Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator ...

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

ACIP recommends extending interval for two-dose series and adding three-dose series in accordance with FDA label ...

The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 ( P <.0001). Changes in other biomarkers, including high-density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein (a), ...

After the initiation of an AID system, glycemic control improved and the effect persisted throughout the study period. (HealthDay News) — Initiation of an automated insulin delivery (AID) system ...

After 3 to 6 months of taking LDOM, all patients had improvement or stability of alopecia. (HealthDay News) — Low-dose oral minoxidil (LDOM) is effective for alopecia in patients with breast ...

The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3%) had existing (prevalent) HSV-2 infections globally in 2020. (HealthDay News ...